G
GC-Rise Pharmaceutical
GC-Rise Pharmaceutical Co., Ltd. is a solely-foreign-owned enterprise invested by INVENTAGES,
About GC-Rise Pharmaceutical
GC-Rise Pharmaceutical Co. Ltd., established in 2008, is a Beijing-based pharmaceutical entity with a strategic focus on women's and children's healthcare in China. The company is led by Chief Executive Officer Wren Zhang. Since its inception, the firm has secured significant financial backing, including a substantial US$15 million in a Series B financing round led by OrbiMed, a prominent healthcare and life sciences investment firm. Other key investors include Inventages and Yifang Venture Capital. This capital has been intended to enhance commercialization capabilities, broaden the product portfolio, and develop an online-to-offline (O2O) platform centered on women and children's health.
The company's business model is centered on providing a comprehensive suite of services for international partners aiming to enter the Chinese market. These services encompass policy interpretation, local registration, management of clinical trials, pricing, distribution, market promotion, and brand development. GC-Rise operates with a specialized focus on five key areas: anti-aging products, respiratory diseases in children, pregnancy and newborn health, skincare products, and mental health and child development. The company also has plans to venture into the point-of-care testing (POCT) market for obstetrics, gynecology, and pediatrics.
GC-Rise possesses a substantial distribution network, with a sales force that covers over 1,000 hospitals in major Chinese cities and distributes products to approximately 10,000 drug stores. The firm's early achievements include being the only pharmaceutical enterprise listed by Deloitte as one of the top 50 fast-growing companies in China for two consecutive years in 2011 and 2012. In 2012, in collaboration with the China Physician Association, GC-Rise initiated the country's first GYN/OB Physician Award. The company has also been involved in launching products like Remifemin, a treatment for menopausal symptoms, in China.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Sep 2014 | $15M | $60M | OrbiMed | — |
| SERIES A✓Equity / VC | Jan 2008 | $4.7M | $19M | INventages Venture Capital | — |
Growth signals
Latest recorded traffic for GC-Rise Pharmaceutical is 160 monthly website visits. GC-Rise Pharmaceutical's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
GC-Rise Pharmaceutical in its local ecosystem
The GC-Rise Pharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
INventages Venture Capital
OrbiMed
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about GC-Rise Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GC-Rise Pharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









